RIGEL - SyK Inhibition Not Good Enough - Limited Market Potential!
RIGL/AZN’s Fostamatinib (FosD, syk inhibitor, PhIII) has again disappointed by not demonstrating better or at par efficacy with approved or competing RA drugs. Despite achieving a statistically significant ACR20 improvement at 24 weeks in a PhIII, OSKIRA-I trial, it failed to demonstrate any statistical significance in its second primary endpoint – change from baseline in mTSS (mTSS = radiographic modified total Sharp score). Last year, AZN and RIGL reported OSKIRA-IV data where FosD failed to achieve superiority to Humira at week 24 based on DAS28 and also failed to show a statistically significant superior DAS28 score at the 100mg BID for a month followed by 100mg QD dose. Positive data on the second endpoint would have differentiated it from other RA drugs. Thus, even if OSKIRA-2 ... For more details, please read our report released on April 5, 2013, titled, “SyK Inhibition Not Good Enough - Limited Market Potential!”
Companies mentioned
Rigel
Companies mentioned
Rigel
